The study tested the experimental medication, fordadistrogene movaparvovec, among about 100 boys aged 4 to 7 with the rare genetic condition. After one year of treatment, the research did not prove efficacy in the primary endpoint — motor function improvement — or in the secondary endpoints — 10-meter run/walk velocity and time to rise from floor velocity.
The safety profile was manageable, Pfizer said in a news release. The drugmaker’s phase 2 trial of fordadistrogene movaparvovec recently paused dosing after a child died.
In summer 2023, the FDA awarded Sarepta Therapeutics the first gene therapy for Duchenne muscular dystrophy.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.